ES2654623T3 - Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan - Google Patents

Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan Download PDF

Info

Publication number
ES2654623T3
ES2654623T3 ES13831176.6T ES13831176T ES2654623T3 ES 2654623 T3 ES2654623 T3 ES 2654623T3 ES 13831176 T ES13831176 T ES 13831176T ES 2654623 T3 ES2654623 T3 ES 2654623T3
Authority
ES
Spain
Prior art keywords
hours
protein
structures
formula
separation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13831176.6T
Other languages
English (en)
Spanish (es)
Inventor
Shaomeng Wang
Rong SHENG
Haiying Sun
Liu Liu
Jianfeng Lu
Donna Mceachern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Application granted granted Critical
Publication of ES2654623T3 publication Critical patent/ES2654623T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
ES13831176.6T 2012-08-23 2013-08-16 Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan Active ES2654623T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692429P 2012-08-23 2012-08-23
US201261692429P 2012-08-23
PCT/US2013/055384 WO2014031487A1 (en) 2012-08-23 2013-08-16 Bivalent inhibitors of iap proteins and therapeutic methods using the same

Publications (1)

Publication Number Publication Date
ES2654623T3 true ES2654623T3 (es) 2018-02-14

Family

ID=50148520

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13831176.6T Active ES2654623T3 (es) 2012-08-23 2013-08-16 Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan

Country Status (12)

Country Link
US (1) US8883771B2 (https=)
EP (1) EP2888265B1 (https=)
JP (1) JP6247298B2 (https=)
KR (2) KR102111704B1 (https=)
CN (3) CN109575049B (https=)
AU (1) AU2013306087B2 (https=)
CA (1) CA2882496C (https=)
ES (1) ES2654623T3 (https=)
HK (1) HK1211030A1 (https=)
MX (1) MX366130B (https=)
RU (1) RU2649975C2 (https=)
WO (1) WO2014031487A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
EP3133069B1 (en) * 2014-04-16 2019-09-18 Shenzhen Yongze Pharmaceutical Co., Ltd. Bcr-abl diploid inhibitor, preparation method therefor, and uses thereof
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3020792A1 (en) 2016-04-20 2017-10-26 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising ripk2 inhibitors
EP3455221B1 (en) * 2016-05-09 2020-03-11 H. Hoffnabb-La Roche Ag Dimeric compounds
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
GB2567126A (en) * 2017-06-23 2019-04-10 Femtogenix Ltd PBC compounds
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
EP4512407A3 (en) 2018-07-13 2025-09-24 F. Hoffmann-La Roche AG Oligonucleotides for modulating rtel1 expression
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
TW202012411A (zh) * 2018-07-31 2020-04-01 大陸商蘇州亞盛藥業有限公司 Iap抑制劑與免疫檢查點分子調節劑的組合用於治療癌症的方法
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
US10870663B2 (en) 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CA3148504A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
MX2022003628A (es) 2019-09-25 2022-07-21 Debiopharm Int Sa Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
CN112891510A (zh) * 2019-11-19 2021-06-04 苏州亚盛药业有限公司 采用iap抑制剂的治疗方法
US20230029259A1 (en) * 2019-12-02 2023-01-26 Ascentage Pharma (Suzhou) Co., Ltd. Combination of iap inhibitors and parp or mek inhibitors or other chemotherapeutic agents
WO2021110136A1 (en) * 2019-12-04 2021-06-10 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
CN114828852A (zh) 2019-12-24 2022-07-29 豪夫迈·罗氏有限公司 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
US20230078120A1 (en) * 2020-05-04 2023-03-16 Ascentage Pharma (Suzhou) Co.,Ltd. Methods for Treating Coronavirus Infections
WO2022012671A1 (en) * 2020-07-16 2022-01-20 Ascentage Pharma (Suzhou) Co., Ltd. The crystalline forms or amorphous forms of bisdiazabicyclic compounds or salts thereof
CN116963732A (zh) * 2021-02-23 2023-10-27 苏州亚盛药业有限公司 药物组合物及其制备方法
EP4382126A4 (en) 2021-08-02 2025-07-30 Ascentage Pharma Suzhou Co Ltd PHARMACEUTICAL COMBINATION AND ITS USE
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
TW202410919A (zh) 2022-05-23 2024-03-16 美商英伊布里克斯公司 Dr5促效劑與iap拮抗劑之組合療法
US12508320B2 (en) 2023-06-29 2025-12-30 SeeCure Taiwan Co., Ltd. Drug conjugate, pharmaceutical composition and method of treating hepatitis
WO2025090605A1 (en) * 2023-10-24 2025-05-01 University Of Houston System Combination of iap inhibitors and cellular kinase inhibitors, such as ponatinib, for use in the treatment of cancer or pulmonary diseases, such as copd, cystic fibrosis, pulmonary fibrosis and covid-19
WO2025261398A1 (en) * 2024-06-19 2025-12-26 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating diseases caused by hiv infection
CN119100970B (zh) * 2024-08-30 2025-09-30 中国药科大学 基于热休克蛋白90的二价抑制剂及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072831A1 (en) * 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
CN1926118A (zh) 2004-03-01 2007-03-07 德克萨斯大学董事会 二聚的小分子细胞凋亡增强剂
CN101128425B (zh) * 2005-02-25 2012-12-26 泰特拉洛吉克药业公司 Iap二聚体抑制剂
JP5230610B2 (ja) * 2006-05-05 2013-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
WO2008128171A2 (en) * 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
ES2643233T3 (es) * 2009-10-23 2017-11-21 The Regents Of The University Of Michigan Miméticos de SMAC bicíclicos diazo bivalentes y los usos de los mismos

Also Published As

Publication number Publication date
CN109485662A (zh) 2019-03-19
CA2882496A1 (en) 2014-02-27
JP2015528447A (ja) 2015-09-28
CN109575049B (zh) 2021-07-30
CN109485662B (zh) 2021-12-21
HK1211030A1 (en) 2016-05-13
EP2888265A1 (en) 2015-07-01
EP2888265A4 (en) 2016-01-27
KR102111704B1 (ko) 2020-05-15
CA2882496C (en) 2020-07-14
US8883771B2 (en) 2014-11-11
WO2014031487A8 (en) 2014-05-30
CN104718209A (zh) 2015-06-17
RU2649975C2 (ru) 2018-04-06
AU2013306087A1 (en) 2015-03-12
US20140057924A1 (en) 2014-02-27
WO2014031487A1 (en) 2014-02-27
EP2888265B1 (en) 2017-10-11
CN109575049A (zh) 2019-04-05
KR20150044937A (ko) 2015-04-27
MX2015002371A (es) 2015-10-05
KR102237888B1 (ko) 2021-04-07
RU2015107552A (ru) 2016-10-10
MX366130B (es) 2019-06-28
KR20200054334A (ko) 2020-05-19
JP6247298B2 (ja) 2017-12-13
AU2013306087B2 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
ES2654623T3 (es) Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan
Pan et al. Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells
Solárová et al. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies
US20130288980A1 (en) Targeting senescent and cancer cells for selective killing by interference with foxo4
AU2018335617B2 (en) Combination of a BTK inhibitor and an inhibitor of CDK9 to treat cancer
US20120130144A1 (en) Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
KR20200078495A (ko) 암 치료를 위한 조성물 및 방법
US20130288981A1 (en) Targeting senescent cells and cancer cells by interference with jnk and/or foxo4
CA3144985A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
RU2682161C2 (ru) Противоопухолевое средство и усилитель противоопухолевого эффекта
Simioni et al. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
AU2009277179A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
JP2019511553A (ja) 静止細胞標的化および有糸分裂の阻害剤を用いた新生物の処置のための組み合わせ
Liu et al. Inhibition of kinesin family member 20B sensitizes hepatocellular carcinoma cell to microtubule‐targeting agents by blocking cytokinesis
Kim et al. Novel biological strategies to enhance the radiation therapeutic ratio
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
WO2021100677A1 (ja) 併用医薬
KR20140056238A (ko) 약제의 병용에 의한 암 치료 방법
ES2353606T3 (es) Uso de la combinación que comprende temozolomida y tnf-alfa para el tratamiento del gioblastoma.
Huang et al. Molecular targeting of growth factor receptor signaling in radiation oncology
CN104815322A (zh) 用于头颈部肿瘤联合治疗的制剂及其用途
US20250375458A1 (en) Compositions and methods to combat multidrug-resistant and persistent t-cell-mediated, oncological and infectious diseases
Ioannidis Investigating the Role of Select Receptors in Radiation-Induced Cellular Plasticity Events in Glioblastoma
JP2008531720A (ja) 過剰増殖疾患のアントラキノンによる治療